{"id":"placebo-and-ssri","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Nausea"},{"rate":"10-20","effect":"Headache"},{"rate":"10-20","effect":"Sexual dysfunction"},{"rate":"10-15","effect":"Insomnia"},{"rate":"8-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Dry mouth"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo and SSRI","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:27:46.381726+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:27:52.023607+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo and SSRI","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:27:52.364578+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1628401/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:27:53.484856+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Selective serotonin reuptake inhibitors (SSRIs) block the serotonin transporter (SERT) on presynaptic neurons, preventing reuptake of serotonin from the synaptic cleft and thereby increasing serotonin availability. Placebo serves as an inert control in this comparative study design. The SSRI component addresses serotonergic dysfunction in mood and anxiety disorders.","oneSentence":"SSRIs increase synaptic serotonin by inhibiting its reuptake, while placebo provides a control comparator with no active pharmacological mechanism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:36:05.685Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:28:10.062422+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Anxiety disorders"}]},"trialDetails":[{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT06559306","phase":"PHASE3","title":"Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-07-25","conditions":"Depressive Disorder, Major","enrollment":752},{"nctId":"NCT07458022","phase":"PHASE2","title":"MAGNESIUM & SSRI VS SSRI ALONE AMONG PATIENTS OF MAJOR DEPRESSIVE DISORDER","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Child Health Sciences and Children's Hospital, Lahore","startDate":"2025-12-01","conditions":"Major Depressive Diorder","enrollment":50},{"nctId":"NCT07139834","phase":"PHASE1","title":"Pattern Separation in Major Depressive Disorder","status":"NOT_YET_RECRUITING","sponsor":"Jeffrey Miller","startDate":"2026-04","conditions":"Major Depressive Disorder (MDD)","enrollment":30},{"nctId":"NCT07359482","phase":"PHASE3","title":"sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19","status":"NOT_YET_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2026-03-01","conditions":"Post-COVID, POST-Covid 19, Post-COVID Conditions","enrollment":160},{"nctId":"NCT05550532","phase":"PHASE3","title":"A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-12-06","conditions":"Depressive Disorder, Major, Anhedonia","enrollment":444},{"nctId":"NCT04183205","phase":"PHASE4","title":"Predicting SSRI Efficacy in Veterans With PTSD","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2019-09-11","conditions":"Posttraumatic Stress Disorder, Major Depressive Disorder","enrollment":26},{"nctId":"NCT06965569","phase":"PHASE1","title":"Multiple Ascending Dose Phase 1 Study of ALA-3000","status":"COMPLETED","sponsor":"Alar Pharmaceuticals Inc.","startDate":"2025-04-21","conditions":"Treatment Resistant Depression","enrollment":37},{"nctId":"NCT03466346","phase":"NA","title":"SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research Project","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-08-31","conditions":"Depression, Unipolar, Posttraumatic Stress Disorder, Trauma","enrollment":2162},{"nctId":"NCT07239011","phase":"PHASE1, PHASE2","title":"Dapagliflozin in Depression","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-01","conditions":"Depression","enrollment":60},{"nctId":"NCT05455684","phase":"PHASE3","title":"A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-06-22","conditions":"Depressive Disorder, Major, Anhedonia","enrollment":513},{"nctId":"NCT01672255","phase":"EARLY_PHASE1","title":"Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-10","conditions":"Type 1 Diabetes, Hypoglycemia Associated Autonomic Failure","enrollment":64},{"nctId":"NCT03228732","phase":"EARLY_PHASE1","title":"The Effects of Fluoxetine and/or DHEA","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2017-12-19","conditions":"Type 1 Diabetes Mellitus","enrollment":60},{"nctId":"NCT06443242","phase":"NA","title":"Efficacy and Safety of Low-dose Laser Acupuncture on Treating Insomnia Associated With Major Depressive Disorder","status":"NOT_YET_RECRUITING","sponsor":"Mohammad Farris Iman Leong Bin Abdullah","startDate":"2025-12-01","conditions":"Major Depressive Disorder, Insomnia","enrollment":120},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":"Depression","enrollment":80},{"nctId":"NCT02685735","phase":"PHASE4","title":"Predicting, Understanding and Speeding Recovery After TKA","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-06-02","conditions":"Pain, Total Knee Replacement, Total Hip Replacement","enrollment":350},{"nctId":"NCT06001021","phase":"NA","title":"Cognitive Behavioral Couple Therapy for Perinatal Distress","status":"COMPLETED","sponsor":"Sameera Shafiq","startDate":"2023-08-15","conditions":"Perinatal Depression, Perinatal Anxiety","enrollment":96},{"nctId":"NCT07120880","phase":"PHASE3","title":"Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-09","conditions":"Major Depressive Disorder (MDD) With Insomnia","enrollment":184},{"nctId":"NCT05895747","phase":"PHASE2","title":"5-HTP and Creatine for Depression R33 Phase","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-09-28","conditions":"Major Depressive Disorder","enrollment":106},{"nctId":"NCT00457197","phase":"PHASE4","title":"Quetiapine for Bipolar Disorder and Alcohol Dependence","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-03","conditions":"Bipolar Disorder, Alcohol Dependence","enrollment":90},{"nctId":"NCT07074652","phase":"NA","title":"The Effect of SSRIs on Threat of Shock Potentiated Neural Circuitry","status":"COMPLETED","sponsor":"UCLH/UCL Joint Research Office","startDate":"2017-12-01","conditions":"Anxiety","enrollment":145},{"nctId":"NCT07067970","phase":"NA","title":"Comparison of the Efficacy and Safety of Dapoxetine, Kegel Exercises, and Acupuncture in the Treatment of Premature Ejaculation: A Randomized, Double-Blind, Placebo-Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Medipol University","startDate":"2025-10-01","conditions":"Premature Ejaculation","enrollment":250},{"nctId":"NCT06081348","phase":"PHASE2","title":"Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders","status":"RECRUITING","sponsor":"Holland Bloorview Kids Rehabilitation Hospital","startDate":"2024-09-16","conditions":"Neurodevelopmental Disorders, Autism, Autism Spectrum Disorder","enrollment":130},{"nctId":"NCT04410341","phase":"PHASE1, PHASE2","title":"The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2020-05-01","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT07057011","phase":"NA","title":"Therapeutic Outcomes of Selective Serotonin Reuptake Inhibitors and Phosphodiesterase-5 Inhibitors Combination Therapy Versus Monotherapy","status":"NOT_YET_RECRUITING","sponsor":"South Valley University","startDate":"2025-07-01","conditions":"Premature Ejaculation","enrollment":60},{"nctId":"NCT06704594","phase":"PHASE4","title":"Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-05-14","conditions":"Premenstrual Dysphoric Disorder (PMDD)","enrollment":288},{"nctId":"NCT05536414","phase":"PHASE2","title":"Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-09-12","conditions":"Major Depressive Disorder","enrollment":337},{"nctId":"NCT05470465","phase":"PHASE1","title":"Effect of Selective Serotonin Reuptake Inhibitors (SSRIs) and an Opioid on Ventilation","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2022-09-01","conditions":"Hypercapnia, Ventilatory Depression","enrollment":27},{"nctId":"NCT03321526","phase":"PHASE2","title":"A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-12","conditions":"Depressive Disorder, Major","enrollment":107},{"nctId":"NCT04951609","phase":"PHASE1","title":"A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-09-02","conditions":"Depressive Disorder, Major","enrollment":31},{"nctId":"NCT06231745","phase":"PHASE3","title":"Paroxetine Safety and Efficacy in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2024-01-31","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT05641623","phase":"PHASE2","title":"OSU6162 as add-on in SSRI/SNRI-resistant Depression","status":"RECRUITING","sponsor":"Göteborg University","startDate":"2022-04-21","conditions":"Depression, Depressive Disorder, Treatment-Resistant, Depressive Disorder","enrollment":180},{"nctId":"NCT06860958","phase":"PHASE3","title":"Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-03-01","conditions":"Depressive Disorder, Major","enrollment":60},{"nctId":"NCT01778686","phase":"NA","title":"Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors","status":"COMPLETED","sponsor":"Gitte Moos Knudsen","startDate":"2013-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT04221997","phase":"PHASE4","title":"Trial With the Treatment of Sertraline in Youth With Generalized, Separation and/or Social Anxiety Disorders.","status":"RECRUITING","sponsor":"University of Cincinnati","startDate":"2019-11-01","conditions":"Anxiety Disorders","enrollment":150},{"nctId":"NCT04395183","phase":"PHASE2","title":"5-HTP and Creatine for Depression","status":"COMPLETED","sponsor":"University of Utah","startDate":"2021-03-01","conditions":"Major Depressive Disorder","enrollment":43},{"nctId":"NCT02134808","phase":"PHASE4","title":"Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder","status":"COMPLETED","sponsor":"Perry Renshaw","startDate":"2014-11-21","conditions":"Major Depressive Disorder","enrollment":71},{"nctId":"NCT05627154","phase":"NA","title":"Combined Antidepressant and Behavioural Intervention","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-05-28","conditions":"Low Mood, Depression, Anxiety","enrollment":134},{"nctId":"NCT02620150","phase":"PHASE4","title":"SSRI Effects on Depression and Immunity in HIV/AIDS","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-02-16","conditions":"Depression, HIV, AIDS","enrollment":108},{"nctId":"NCT01479829","phase":"PHASE4","title":"Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression","status":"COMPLETED","sponsor":"Loyola University","startDate":"2011-03-23","conditions":"Bipolar Depression","enrollment":100},{"nctId":"NCT01032083","phase":"PHASE4","title":"Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2011-07","conditions":"Schizophrenia","enrollment":62},{"nctId":"NCT06212284","phase":"NA","title":"Serotonin, Anxiety and Visceral Sensation","status":"COMPLETED","sponsor":"University of Sussex","startDate":"2018-02-18","conditions":"Healthy","enrollment":31},{"nctId":"NCT00533117","phase":"PHASE4","title":"Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2001-03","conditions":"Borderline Personality Disorder","enrollment":91},{"nctId":"NCT05181527","phase":"PHASE4","title":"Repurposing of Dextromethorphan as an Adjunct Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2022-02-10","conditions":"Major Depressive Disorder","enrollment":60},{"nctId":"NCT02767999","phase":"PHASE4","title":"Serotonin Selective Reuptake Inhibitor (SSRI) Effects on Cerebral Connectivity in Acute Ischemic Stroke","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2017-02-27","conditions":"Stroke","enrollment":25},{"nctId":"NCT04975100","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2021-08-26","conditions":"Major Depressive Disorder","enrollment":60},{"nctId":"NCT05957094","phase":"NA","title":"Human Cerebral Blood Flow and Serotonin","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2023-08","conditions":"Depression, Serotonin Deficiency","enrollment":15},{"nctId":"NCT02530164","phase":"NA","title":"Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2015-09","conditions":"Major Depressive Disorder, Unipolar Depression, Depression","enrollment":163},{"nctId":"NCT01644747","phase":"PHASE2","title":"tDCS as an add-on Treatment for Resistant Major Depression in Uni- or Bipolar Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2012-07-19","conditions":"Resistant Depression, Moods Disorders, Unipolar Depression","enrollment":87},{"nctId":"NCT05850572","phase":"NA","title":"A Study of the Efficacy of Fecal Microbiota Transplantation(FMT) in the Treatment of Depression","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-07","conditions":"Depression","enrollment":100},{"nctId":"NCT05789186","phase":"EARLY_PHASE1","title":"Clinical Study of Cang Ai Volatile Oil (CAVO) on Mild to Moderate Depression in Children and Adolescents","status":"UNKNOWN","sponsor":"Chen Qian","startDate":"2023-05-01","conditions":"Depression","enrollment":108},{"nctId":"NCT01769027","phase":"PHASE2","title":"Antibiotic Treatment and Intravenous Immunoglobulin Trial for PANDAS","status":"WITHDRAWN","sponsor":"CNS Onlus","startDate":"2013-06","conditions":"Pandas","enrollment":""},{"nctId":"NCT05730062","phase":"PHASE1","title":"Influence of Oxycodone on Individuals Taking an SSRI","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2023-03-15","conditions":"Opioid Induced Respiratory Depression, Depressive Disorder, Anxiety Disorders","enrollment":55},{"nctId":"NCT01309074","phase":"PHASE4","title":"Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2009-11","conditions":"Epilepsy, Anxiety","enrollment":""},{"nctId":"NCT02623205","phase":"PHASE4","title":"Advancing Personalized Antidepressant Treatment Using PET/MRI","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2015-05","conditions":"Depression","enrollment":85},{"nctId":"NCT02674529","phase":"PHASE2, PHASE3","title":"Study of Neural Responses Induced by Antidepressant Effects","status":"COMPLETED","sponsor":"Marta Peciña, MD PhD","startDate":"2016-09","conditions":"Major Depressive Disorder","enrollment":60},{"nctId":"NCT04019704","phase":"PHASE3","title":"A Trial of AXS-05 in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2019-06-20","conditions":"Depression, Major Depressive Disorder","enrollment":327},{"nctId":"NCT04069819","phase":"NA","title":"The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2019-08-01","conditions":"Major Depressive Disorder","enrollment":80},{"nctId":"NCT02972398","phase":"NA","title":"N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders","status":"UNKNOWN","sponsor":"Tianjin Anding Hospital","startDate":"2015-09","conditions":"Major Depressive Disorders","enrollment":200},{"nctId":"NCT04592159","phase":"PHASE2, PHASE3","title":"Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder","status":"WITHDRAWN","sponsor":"Jazz Pharmaceuticals","startDate":"2021-02-01","conditions":"Post-Traumatic Stress Disorder","enrollment":""},{"nctId":"NCT02922725","phase":"PHASE4","title":"Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females","status":"TERMINATED","sponsor":"Brent Michael Kious, MD, PhD","startDate":"2016-11","conditions":"Major Depressive Disorder","enrollment":32},{"nctId":"NCT05352113","phase":"NA","title":"Intradermal Needle Therapy for Major Depressive Disorder","status":"UNKNOWN","sponsor":"The Third Affiliated hospital of Zhejiang Chinese Medical University","startDate":"2022-05-01","conditions":"Major Depressive Disorder","enrollment":120},{"nctId":"NCT03812588","phase":"PHASE4","title":"Contact: Developing New Clinical Management Strategies","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2019-01-30","conditions":"Major Depressive Disorder","enrollment":29},{"nctId":"NCT04880460","phase":"PHASE2","title":"Effect of Magnesium Supplementation in Selective Serotonin Reuptake Inhibitors Treated Major Depressive Disorder Patients","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2021-03-18","conditions":"MDD","enrollment":90},{"nctId":"NCT05216614","phase":"PHASE2","title":"Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2021-12-14","conditions":"COVID-19, Olfactory Disorder, Parosmia","enrollment":""},{"nctId":"NCT04904952","phase":"NA","title":"Effect of N-acetylcysteine as Add on Therapy With SSRI in Moderate to Severe OCD Patients","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2020-03-13","conditions":"OCD","enrollment":60},{"nctId":"NCT03249311","phase":"PHASE4","title":"Levomilnacipran in Healthy Males","status":"UNKNOWN","sponsor":"University of Ottawa","startDate":"2018-03-02","conditions":"None (i.e. Healthy Volunteers)","enrollment":36},{"nctId":"NCT05041582","phase":"PHASE3","title":"SSRIs and TDCS Enhance Post-stroke Motor Recovery","status":"UNKNOWN","sponsor":"Chih-Wei Tang","startDate":"2021-09-01","conditions":"Stroke, Motor","enrollment":80},{"nctId":"NCT04221256","phase":"PHASE1, PHASE2","title":"Dose-finding Study of Selective Serotonin Reuptake Inhibitors to Enhance Neuroplasticity","status":"WITHDRAWN","sponsor":"Burke Medical Research Institute","startDate":"2020-03-11","conditions":"Stroke, Ischemic","enrollment":""},{"nctId":"NCT02516332","phase":"NA","title":"Exercise and Pharmacotherapy for Anxiety in Cardiac Patients","status":"COMPLETED","sponsor":"Duke University","startDate":"2015-12","conditions":"Anxiety, Cardiovascular Disease","enrollment":128},{"nctId":"NCT02092974","phase":"PHASE1","title":"Mechanism of tDCS-induced Learning Enhancement - the Role of Serotonin","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2014-04","conditions":"Healthy Young and Older Adults","enrollment":40},{"nctId":"NCT03469128","phase":"PHASE1","title":"Cognitive Processing Therapy vs. Sertraline for the Treatment of PTSD & SUD in Egyptian Patients","status":"COMPLETED","sponsor":"British University In Egypt","startDate":"2016-01-01","conditions":"Psychologic Manipulation","enrollment":150},{"nctId":"NCT04482296","phase":"NA","title":"Effect of Zinc Supplementation on Depression in SSRI-treated Major Depressive Disorder Patients","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2019-09-15","conditions":"MDD","enrollment":100},{"nctId":"NCT04676139","phase":"PHASE3","title":"The Safety and Efficacy of Fluoxetine for Refractory Primary Mono-symptomatic Nocturnal Enuresis in Children","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2020-07-01","conditions":"Nocturnal Enuresis","enrollment":100},{"nctId":"NCT03414931","phase":"PHASE2","title":"NMDA Modulation in Major Depressive Disorder in Late- Life","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2016-01","conditions":"Depressive Disorder, Major","enrollment":136},{"nctId":"NCT04531423","phase":"NA","title":"PKC as Serum Biomarkers for Depression","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2020-10-01","conditions":"Major Depressive Disorder","enrollment":100},{"nctId":"NCT04246905","phase":"PHASE2","title":"A 12-weeks Study to Evaluate Sulforaphane in the Treatment of Depression","status":"UNKNOWN","sponsor":"Central South University","startDate":"2020-07-15","conditions":"Depressive Disorder","enrollment":90},{"nctId":"NCT01931202","phase":"NA","title":"Mechanisms of Antidepressant Non-Response in Late-Life Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2014-02-19","conditions":"Major Depressive Disorder","enrollment":138},{"nctId":"NCT03397771","phase":"PHASE1, PHASE2","title":"DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence","status":"COMPLETED","sponsor":"Ixaltis SA","startDate":"2018-04-03","conditions":"Urinary Incontinence","enrollment":84},{"nctId":"NCT03274817","phase":"PHASE1","title":"A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2009-06-18","conditions":"Alzheimer Disease","enrollment":5},{"nctId":"NCT02929667","phase":"PHASE2","title":"Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI","status":"COMPLETED","sponsor":"Rup Kamal Sainju","startDate":"2017-02-16","conditions":"Epilepsy, SUDEP","enrollment":30},{"nctId":"NCT00539513","phase":"PHASE2","title":"N-Acetylcysteine Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder","status":"TERMINATED","sponsor":"Yale University","startDate":"2006-06","conditions":"Obsessive-Compulsive Disorder","enrollment":10},{"nctId":"NCT02865642","phase":"PHASE2","title":"Cortical Ischemic Stroke and Serotonin","status":"UNKNOWN","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2016-08","conditions":"Stroke","enrollment":90},{"nctId":"NCT00523718","phase":"PHASE2","title":"Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder","status":"COMPLETED","sponsor":"Yale University","startDate":"2006-09","conditions":"Obsessive-compulsive Disorder, Ocd","enrollment":40},{"nctId":"NCT01204918","phase":"PHASE2","title":"Efficacy and Tolerability of Riluzole in Treatment Resistant Depression","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-06","conditions":"Depression","enrollment":104},{"nctId":"NCT00262223","phase":"PHASE2","title":"Combined Treatment for Alcohol-Dependent Individuals With PTSD","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2006-05","conditions":"Stress Disorders, Post-Traumatic, Alcohol Abuse, Substance-Related Disorders","enrollment":69},{"nctId":"NCT02223299","phase":"NA","title":"Pilot Study: Combining Nutritional Supplements With Standard Antidepressant to Treat Depression.","status":"WITHDRAWN","sponsor":"John D. Dingell VA Medical Center","startDate":"2015-11","conditions":"Depression","enrollment":""},{"nctId":"NCT02109939","phase":"NA","title":"Genomics Used to Improve DEpression Decisions","status":"COMPLETED","sponsor":"Assurex Health Inc.","startDate":"2014-04","conditions":"Major Depressive Disorder (MDD)","enrollment":1398},{"nctId":"NCT03179839","phase":"NA","title":"The Study of Mindfulness Based Cognitive Therapy and Obsessive-Compulsive Disorder","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2017-01-20","conditions":"Obsessive-Compulsive Disorder","enrollment":123},{"nctId":"NCT02805439","phase":"PHASE2","title":"Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant Treatment","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2016-03","conditions":"Major Depressive Disorder","enrollment":400},{"nctId":"NCT01041274","phase":"PHASE4","title":"DECIFER: Depression and Citalopram In First Episode Recovery","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2010-01","conditions":"Schizophrenia, Schizophreniform Disorder","enrollment":95},{"nctId":"NCT00296517","phase":"PHASE3","title":"Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-19","conditions":"Depressive Disorder","enrollment":325},{"nctId":"NCT03018340","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)","status":"COMPLETED","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2016-12","conditions":"Adjunctive Treatment of Major Depressive Disorder","enrollment":207},{"nctId":"NCT01695291","phase":"PHASE2","title":"Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2012-05","conditions":"Obsessive Compulsive Disorder","enrollment":31},{"nctId":"NCT00642694","phase":"PHASE3","title":"Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-05","conditions":"Major Depressive Disorder, Insomnia","enrollment":29},{"nctId":"NCT01657760","phase":"PHASE1","title":"Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2014-05-01","conditions":"Alcohol Dependence","enrollment":31},{"nctId":"NCT00994786","phase":"PHASE4","title":"A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder","status":"COMPLETED","sponsor":"McMaster University","startDate":"2009-01","conditions":"Obsessive-Compulsive Disorder","enrollment":15},{"nctId":"NCT01103180","phase":"PHASE2","title":"Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2010-09","conditions":"Borderline Personality Disorder","enrollment":70},{"nctId":"NCT01788969","phase":"PHASE1","title":"Serotonergic Modulation of Motor Function in Subacute and Chronic SCI","status":"UNKNOWN","sponsor":"Shirley Ryan AbilityLab","startDate":"2005-06","conditions":"Spinal Cord Injury","enrollment":42},{"nctId":"NCT02153567","phase":"PHASE3","title":"SSRI Study for Functional Dyspepsia (SS)","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2013-12-06","conditions":"Dyspepsia, Anxiety, Depression","enrollment":71}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1628401"},"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo and SSRI","genericName":"Placebo and SSRI","companyName":"All India Institute of Medical Sciences, Bhubaneswar","companyId":"all-india-institute-of-medical-sciences-bhubaneswar","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SSRIs increase synaptic serotonin by inhibiting its reuptake, while placebo provides a control comparator with no active pharmacological mechanism. Used for Major depressive disorder, Anxiety disorders.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:28:10.062422+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}